Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Paul DeSouza"'
Autor:
Benedicte Grebstad Tune, Heena Sareen, Branka Powter, Smadar Kahana-Edwin, Adam Cooper, Eng-Siew Koh, Cheok S. Lee, Joseph W. Po, Geoff McCowage, Mark Dexter, Lucy Cain, Geraldine O’Neill, Victoria Prior, Jonathan Karpelowsky, Maria Tsoli, Lars O. Baumbusch, David Ziegler, Tara L. Roberts, Paul DeSouza, Therese M. Becker, Yafeng Ma
Publikováno v:
Biomedicines, Vol 11, Iss 11, p 2907 (2023)
Genetic histone variants have been implicated in cancer development and progression. Mutations affecting the histone 3 (H3) family, H3.1 (encoded by HIST1H3B and HIST1H3C) and H3.3 (encoded by H3F3A), are mainly associated with pediatric brain cancer
Externí odkaz:
https://doaj.org/article/444c9199ff6b4d05bfdb45dd6101a100
Autor:
Marra Jai Aghajani, Tara Laurine Roberts, Tao Yang, Charles Eugenio McCafferty, Nicole J Caixeiro, Paul DeSouza, Navin Niles
Publikováno v:
Endocrine Connections, Vol 8, Iss 7, Pp 1040-1051 (2019)
To date, no research evaluating the predictive capabilities of soluble programmed cell death-ligand 1 (sPD-L1) in thyroid cancer patients has been performed. We aimed to investigate the prognostic significance of sPD-L1 expression in papillary thyroi
Externí odkaz:
https://doaj.org/article/11e1c36b25244322a5eb2a3e83967d2c
Autor:
Tara L. Roberts, Tao Yang, Charles Eugenio McCafferty, Navin Niles, Marra Jai Aghajani, Paul DeSouza, Nicole J. Caixeiro
Publikováno v:
Endocrine Connections, Vol 8, Iss 7, Pp 1040-1051 (2019)
Endocrine Connections
Endocrine Connections
To date, no research evaluating the predictive capabilities of soluble programmed cell death-ligand 1 (sPD-L1) in thyroid cancer patients has been performed. We aimed to investigate the prognostic significance of sPD-L1 expression in papillary thyroi
Autor:
Tao Yang, Christina Abdel Shaheed, Susannah Graham, Navin Niles, Paul DeSouza, Tara L. Roberts, Miss Marra Aghajani, Charles Eugenio McCafferty
Publikováno v:
Thyroid. 28:349-361
Evidence has shown that programmed cell death ligand 1 (PD-L1) overexpression is associated with poor prognosis and resistance to immune therapies in several human cancers. However, data on the prognostic significance of PD-L1 expression in thyroid c
Autor:
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M O'Rourke, Mark Wong, Mark G Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D Turner, Michael J Yellin, Tibor Keler, Thomas A Davis, Roger Stupp, John H Sampson, Jian Campian, Lawrence Recht, Samuel Goldlust, Kevin Becker, Gene Barnett, Garth Nicholas, Annick Desjardins, Tara Benkers, Naveed Wagle, Morris Groves, Santosh Kesari, Zsolt Horvath, Ryan Merrell, Richard Curry, James O'Rourke, David Schuster, Maciej Mrugala, Randy Jensen, John Trusheim, Glenn Lesser, Karl Belanger, Andrew Sloan, Benjamin Purow, Karen Fink, Jeffrey Raizer, Michael Schulder, Suresh Nair, Scott Peak, Alba Brandes, Nimish Mohile, Joseph Landolfi, Jon Olson, Ross Jennens, Paul DeSouza, Bridget Robinson, Marka Crittenden, Kent Shih, Alexandra Flowers, Shirley Ong, Jennifer Connelly, Costas Hadjipanayis, Pierre Giglio, Frank Mott, David Mathieu, Nathalie Lessard, Sanchez Juan Sepulveda, József Lövey, Helen Wheeler, Po-Ling Inglis, Claire Hardie, Daniela Bota, Maciej Lesniak, Jana Portnow, Bruce Frankel, Larry Junck, Reid Thompson, Lawrence Berk, John McGhie, David Macdonald, Frank Saran, Riccardo Soffietti, Deborah Blumenthal, Sá Barreto Costa Marcos André de, Anna Nowak, Nimit Singhal, Andreas Hottinger, Andrea Schmid, Gordan Srkalovic, David Baskin, Camilo Fadul, Louis Nabors, Renato LaRocca, John Villano, Nina Paleologos, Petr Kavan, Marshall Pitz, Brian Thiessen, Ahmed Idbaih, Jean Sébastien Frenel, Julien Domont, Oliver Grauer, Peter Hau, Christine Marosi, Jan Sroubek, Elizabeth Hovey, P.S. Sridhar, Lawrence Cher, Erin Dunbar, Thomas Coyle, Jane Raymond, Kevin Barton, Michael Guarino, Sumul Raval, Baldassarre Stea, Jorge Dietrich, Kirsten Hopkins, Sara Erridge, Joachim-Peter Steinbach, Losada Estela Pineda, Quintero Carmen Balana, Barco Berron Sonia del, Miklós Wenczl, Katalin Molnár, Katalin Hideghéty, Alexander Lossos, Linde Myra van, Ana Levy, Rosemary Harrup, William Patterson, Zarnie Lwin, Sith Sathornsumetee, E-Jian Lee, Jih-Tsun Ho, Steven Emmons, J. Paul Duic, Spencer Shao, Hani Ashamalla, Michael Weaver, Jose Lutzky, Nicholas Avgeropoulos, Wahid Hanna, Mukund Nadipuram, Gary Cecchi, Robert O'Donnell, Susan Pannullo, Jennifer Carney, Mark Hamilton, Mary MacNeil, Ronald Beaney, Michel Fabbro, Oliver Schnell, Rainer Fietkau, Guenther Stockhammer, Bela Malinova, Karel Odrazka, Martin Sames, Gil Miguel Gil, Evangelia Razis, Konstantin Lavrenkov, Guillermo Castro, Francisco Ramirez, Clarissa Baldotto, Fabiana Viola, Suzana Malheiros, Jason Lickliter, Stanislaw Gauden, Arunee Dechaphunkul, Iyavut Thaipisuttikul, Ziad Thotathil, Hsin-I Ma, Wen-Yu Cheng, Chin-Hong Chang, Fernando Salas, Pierre-Yves Dietrich, Christoph Mamot, Lakshmi Nayak, Shona Nag
Publikováno v:
The Lancet Oncology, Vol. 18, No 10 (2017) pp. 1373-1385
The Lancet. Oncology, vol 18, iss 10
The Lancet. Oncology, vol 18, iss 10
Summary Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b6b5ae20a38597b1d233965368e0708
https://doi.org/10.5167/uzh-141081
https://doi.org/10.5167/uzh-141081
Autor:
Suzanne K. Chambers, Shomik Sengupta, Paul DeSouza, Scott Williams, Dickon Hayne, Margaret McJannett, Ian D. Davis, Peter Grimison, Martin R. Stockler, Guy C. Toner
Publikováno v:
BJU international. 115(6)